Interactive + Gaming

CLICK HERE TO REGISTER FOR THIS EVENT

Innovation vs. Patentability

On December 1, 2016, Partner Jeffrey Snow will serve as a panelist at a program hosted by Pryor Cashman and Partner Stephen Goodman entitled "Innovation vs. Patentability – The Unique Challenges of Protecting New Concepts in the U.S."

Snow will be joined by co-panelists Alan Morrison, Arikha Moses and Brian Yarnell to discuss the real-world challenges raised by seminal patent cases Alice Corp. v. CLS Bank International (2014); Association for Molecular Pathology v. Myriad Genetics, Inc. (2013); and Mayo Collaborative Services v. Prometheus Laboratories (2012). Additionally, the panel will debate potential strategies for obtaining patent protection despite the effects that these cases have had on the U.S. patent landscape.

At the conclusion of the panel, guests will be invited to enjoy hors d'oeuvres and cocktails.

 

More About the Panelists

Stephen Goodman (Moderator) is a partner in Pryor Cashman’s Corporate Group, co-chair of the Life Sciences and Emerging Companies practices, and co-founder of Mid Atlantic Bio Angels (MABA), an invitation-only angel investor group focused exclusively on new and emerging life science companies. He represents entrepreneurs, emerging entities and multinational healthcare, software and technology-based companies, many of whom rely on patent and technology licensing to fuel their business models. 

Steve obtained his JD from New York University School of Law, where he was elected to the Order of the Coif, and his BA, with honors, from The University of Chicago. He serves on the business advisory board of the Institute for the Study of Aging/Alzheimer’s Drug Discovery Foundation, and is a mentor at Columbia Business School’s Eugene Lang Entrepreneurship Center.

Jeffrey Snow is a partner in Pryor Cashman’s Intellectual Property, Digital Media and Litigation Groups. He handles a wide variety of patent litigations and prosecutions for domestic and international clients involving infringement, validity, enforceability and ownership issues. Jeff is frequently called upon by the media to comment on developments in patent law. His clients hail from a range of sectors and industries including software, engineering, wireless communications, utilities, optics, gaming, e-Commerce and medical device manufacturing, among others. 

Jeff obtained his JD from Harvard Law School, where he served as editor of the Harvard Journal of Law and Technology, and his ScB, cum laude, from Brown University. 

Arikha Moses, PhD, is a seasoned executive with 15+ years of experience creating and leading medtech companies. Dr. Moses started her career with a seed-stage venture firm, where she was responsible for sourcing, building, and managing early-stage life science companies including TyRx and EluSys Therapeutics. She subsequently spent more than 10 years growing TyRx from a virtual company through to the commercialization of multiple drug-eluting devices. TyRx was sold to Medtronic. She has also worked with the venture capital firm the Vertical Group as an EIR, where she assisted with due diligence on investments in both private and public companies. While working with Vertical, she founded and led Galatea Surgical, a plastic surgery company, through its clinical and commercial product sales. 

Arikha received a PhD in Chemistry from Yale University and a BA with Honors in Chemistry from Brandeis University.

Jim Chinitz is the CEO and co-founder of Population Diagnostics, a company focused on the research of human genetics to develop DNA-based diagnostics and enable precision medicine. He has held positions at Hoffmann-La Roche, Applied Biosystems ["ABI"] (acquired by Thermo Fisher Scientific), Affymetrix (acquired by Thermo Fisher), Third Wave Technologies (acquired by Hologic) and Enzo Life Sciences, including director and executive management level positions. He has played essential roles in the commercialization and launches of pioneering platforms such as DNA sequencing, PCR, microarray, gene expression and genotyping technologies that were integral tools adopted for the Human Genome Project and today are the mainstream tools and methods used for human disease research.

Brian Yarnell, President and founder of Bluestream Health, is an entrepreneur with 15 years of experience creating and commercializing enterprise technology. Prior to launching Bluestream Health in 2015, he founded and managed StarlingHealth, a startup that replaced nurse call systems with multilingual touchscreen interfaces and a clinical workflow platform. In 2014, Brian oversaw the acquisition of StarlingHealth by Hill-Rom. 

Brian has also created technology solutions for advertising technology, marketing automation, consumer insights, business intelligence and data analytics. He is passionate about applying this experience to transform healthcare delivery, sits on the advisory board for the NYEDC’s ELabNYC and is a mentor to several startups. Brian earned a BS in Marketing and International Business from The Pennsylvania State University. 

Alan J. Morrison founded the Law Offices of Alan J. Morrison in 2014. Prior to that, he was a partner at Cozen O’Connor, Cohen, Pontani, Lieberman & Pavane LLP and Cooper & Dunham LLP, and was in-house counsel at Johnson & Johnson. Alan has undergraduate and graduate degrees in biochemistry, and counsels his clients on patents and transactional law in the biotechnology and pharmaceutical fields. In his more than 20 years of practice, he has represented some of the world’s largest, most prestigious and most innovative companies and institutions. 

Alan is also a faculty member in the Department of Biological Sciences at Columbia University where he teaches two graduate courses – “Biotechnology Law” and “Ethics in Biopharmaceutical Patent and Regulatory Law.” These courses, which he designed, are the first of their kind at Columbia.